Larkin, J., & Hassel, J. C. (2018). Overall survival in patients with advanced melanoma who received Nivolumab versus investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial. Journal of clinical oncology, 36(4), . https://doi.org/10.1200/JCO.2016.71.8023
Chicago Style (17th ed.) CitationLarkin, James, and Jessica C. Hassel. "Overall Survival in Patients with Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-label Phase III Trial." Journal of Clinical Oncology 36, no. 4 (2018). https://doi.org/10.1200/JCO.2016.71.8023.
MLA (9th ed.) CitationLarkin, James, and Jessica C. Hassel. "Overall Survival in Patients with Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-label Phase III Trial." Journal of Clinical Oncology, vol. 36, no. 4, 2018, https://doi.org/10.1200/JCO.2016.71.8023.